{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T15:58:05Z","timestamp":1762012685478,"version":"build-2065373602"},"reference-count":39,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Mol Med"],"DOI":"10.3892\/ijmm.2019.4190","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T09:52:26Z","timestamp":1557395546000},"source":"Crossref","is-referenced-by-count":6,"title":["EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR"],"prefix":"10.3892","author":[{"given":"San\u2011Hu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue\u2011Fang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi\u2011Bin","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2019,5,9]]},"reference":[{"key":"key20200713170957_b1-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jss.2009.04.048","article-title":"Effects of epidermal growth factor receptor inhibitor genistein on proliferative cholangitis in rats","volume":"162","author":"Jiang","year":"2010","journal-title":"J Surg Res"},{"key":"key20200713170957_b2-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/j.1440-1746.2008.05688.x","article-title":"Proliferating cell nuclear antigen shRNA treatment attenuates chronic proliferative cholangitis in rats","volume":"24","author":"Li","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"key20200713170957_b3-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00268-009-0154-8","article-title":"Significance of controlling chronic proliferative cholangitis in the treatment of hepatolithiasis","volume":"33","author":"Li","year":"2009","journal-title":"World J Surg"},{"key":"key20200713170957_b4-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"A246","DOI":"10.1016\/S0016-5085(03)81234-9","article-title":"Involvement of prostaglandin E2 and its specific receptor subtype EP4 in chronic proliferative cholangitis in the bile ducts of patients with hepatolithiasis","volume":"124","author":"Asano","year":"2003","journal-title":"Gastroenterology"},{"key":"key20200713170957_b5-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"536081","DOI":"10.1155\/2013\/536081","article-title":"Recurrent pyogenic cholangitis: Disease characteristics and patterns of recurrence","volume":"2013","author":"Koh","year":"2013","journal-title":"ISRN Surg"},{"key":"key20200713170957_b6-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jss.2005.02.029","article-title":"The practical value of applying chemical biliary duct embolization to chemical hepatectomy for treatment of hepatolithiasis","volume":"127","author":"Li","year":"2005","journal-title":"J Surg Res"},{"key":"key20200713170957_b7-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.2010.29.2847","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: Dose-finding study for the prospective multicenter, randomized, phase II\/III REAL-3 trial","volume":"28","author":"Okines","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20200713170957_b8-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","article-title":"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer","volume":"26","author":"Di Nicolantonio","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20200713170957_b9-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20200713170957_b10-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/CAD.0b013e32800feecb","article-title":"Panitumumab the first fully human monoclonal antibody: From the bench to the clinic","volume":"18","author":"Cohenuram","year":"2007","journal-title":"Anticancer Drugs"},{"key":"key20200713170957_b11-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2165\/11205090-000000000-00000","article-title":"Panitumumab: A review of its use in metastatic colorectal cancer","volume":"70","author":"Keating","year":"2010","journal-title":"Drugs"},{"key":"key20200713170957_b12-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20200713170957_b13-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/cncr.22915","article-title":"Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer","volume":"110","author":"Hecht","year":"2007","journal-title":"Cancer"},{"key":"key20200713170957_b14-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jss.2009.09.058","article-title":"Epidermal growth factor receptor as a target for anti-proliferative treatment of proliferative cholangitis in hepatolithiasis","volume":"166","author":"Li","year":"2011","journal-title":"J Surg Res"},{"key":"key20200713170957_b15-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"8081","DOI":"10.3748\/wjg.v21.i26.8081","article-title":"Ischemic preconditioning ameliorates intestinal injury induced by ischemia-reperfusion in rats","volume":"21","author":"Ji","year":"2015","journal-title":"World J Gastroenterol"},{"key":"key20200713170957_b16-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20200713170957_b17-ijmm-44-01-0079","first-page":"417","article-title":"Mucus histochemical study of bilirubin cholangiolithiasis in rabbit model","volume":"20","author":"Li","year":"1989","journal-title":"Hua Xi Yi Ke Da Xue Xue Bao"},{"key":"key20200713170957_b18-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/BF02208665","article-title":"Cholelithiasis in Taiwan. Gallstone characteristics, surgical incidence, bile lipid composition, and role of beta-glucuronidase","volume":"40","author":"Ho","year":"1995","journal-title":"Dig Dis Sci"},{"key":"key20200713170957_b19-ijmm-44-01-0079","first-page":"1477","article-title":"Practical value of applying cdc2 kinase shRNA to chronic proliferative cholangitis in treatment of hepatolithiasis","volume":"56","author":"Li","year":"2009","journal-title":"Hepatogastroenterology"},{"key":"key20200713170957_b20-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3748\/wjg.15.95","article-title":"Treatment of chronic proliferative cholangitis with c-myc shRNA","volume":"15","author":"Li","year":"2009","journal-title":"World J Gastroenterol"},{"key":"key20200713170957_b21-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1158\/1078-0432.CCR-05-1692","article-title":"Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma","volume":"12","author":"Leone","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20200713170957_b22-ijmm-44-01-0079","first-page":"915","article-title":"The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines","volume":"28","author":"Miyata","year":"2006","journal-title":"Int J Oncol"},{"key":"key20200713170957_b23-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/1541-7786.MCR-11-0531","article-title":"In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy","volume":"10","author":"Gajadhar","year":"2012","journal-title":"Mol Cancer Res"},{"key":"key20200713170957_b24-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2036.2008.03717.x","article-title":"Review article: Panitumumab-a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"key20200713170957_b25-ijmm-44-01-0079","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/000313481007600118","article-title":"An immunohisto-chemical study of osteopontin in pigment gallstone formation","volume":"76","author":"Imano","year":"2010","journal-title":"Am Surg"},{"key":"key20200713170957_b26-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"L1049","DOI":"10.1152\/ajplung.00388.2004","article-title":"E-cadherin promotes EGFR-mediated cell differentiation and MUC5AC mucin expression in cultured human airway epithelial cells","volume":"289","author":"Kim","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"key20200713170957_b27-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1165\/rcmb.2011-0405OC","article-title":"Influenza A induces the major secreted airway mucin MUC5AC in a protease-EGFR-extracellular regulated kinase-Sp1-dependent pathway","volume":"47","author":"Barbier","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"key20200713170957_b28-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1073\/pnas.0408932102","article-title":"Dual oxidase 1-dependent MUC5AC mucin expression in cultured human airway epithelial cells","volume":"102","author":"Shao","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713170957_b29-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/jcp.20494","article-title":"Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells","volume":"206","author":"Bullwinkel","year":"2006","journal-title":"J Cell Physiol"},{"key":"key20200713170957_b30-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1227\/01.NEU.0000349930.66434.82","article-title":"Ki-67 in pituitary neoplasms: A review-part I","volume":"65","author":"Salehi","year":"2009","journal-title":"Neurosurgery"},{"key":"key20200713170957_b31-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.12659\/MSM.894330","article-title":"Expression and significance of COX-2 and Ki-67 in hepatolithiasis with bile duct carcinoma","volume":"21","author":"Wang","year":"2015","journal-title":"Med Sci Monit"},{"key":"key20200713170957_b32-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jconrel.2015.04.029","article-title":"A collagen-binding EGFR single-chain Fv antibody fragment for the targeted cancer therapy","volume":"209","author":"Liang","year":"2015","journal-title":"J Control Release"},{"key":"key20200713170957_b33-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/15321810701212088","article-title":"Immunodetection of collagen types I, II, III, and IV for differentiation of liver fibrosis stages in patients with chronic HCV","volume":"28","author":"Attallah","year":"2007","journal-title":"J Immunoassay Immunochem"},{"key":"key20200713170957_b34-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"F822","DOI":"10.1152\/ajprenal.00054.2009","article-title":"EGFR-PLCgamma1 signaling mediates high glucose-induced PKCbeta1-Akt activation and collagen I upregulation in mesangial cells","volume":"297","author":"Wu","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"key20200713170957_b35-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1158\/1535-7163.MCT-14-0212","article-title":"PET imaging of beta-glucuronidase activity by an activity-based 124I-trapping probe for the personalized glucuronide prodrug targeted therapy","volume":"13","author":"Su","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"key20200713170957_b36-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1038\/s41598-017-03252-4","article-title":"Real-time imaging of intestinal bacterial \u03b2-glucuronidase activity by hydrolysis of a fluorescent probe","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"key20200713170957_b37-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"key20200713170957_b38-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Feldman","year":"2009","journal-title":"PLoS Biol"},{"key":"key20200713170957_b39-ijmm-44-01-0079","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/sj.bjc.6605761","article-title":"Dual inhibition of EGFR and mTOR pathways in small cell lung cancer","volume":"103","author":"Schmid","year":"2010","journal-title":"Br J Cancer"}],"container-title":["International Journal of Molecular Medicine"],"original-title":[],"deposited":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T22:06:36Z","timestamp":1607724396000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijmm.2019.4190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,9]]},"references-count":39,"URL":"https:\/\/doi.org\/10.3892\/ijmm.2019.4190","relation":{},"ISSN":["1107-3756","1791-244X"],"issn-type":[{"type":"print","value":"1107-3756"},{"type":"electronic","value":"1791-244X"}],"subject":[],"published":{"date-parts":[[2019,5,9]]}}}